7.68
前日終値:
$7.51
開ける:
$7.39
24時間の取引高:
6.99M
Relative Volume:
2.26
時価総額:
$1.02B
収益:
$631.73M
当期純損益:
$-239.78M
株価収益率:
-3.802
EPS:
-2.02
ネットキャッシュフロー:
$-33.45M
1週間 パフォーマンス:
-7.19%
1か月 パフォーマンス:
-26.08%
6か月 パフォーマンス:
-50.03%
1年 パフォーマンス:
-72.51%
10 X Genomics Inc Stock (TXG) Company Profile
名前
10 X Genomics Inc
セクター
電話
(925) 401-7300
住所
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
TXG を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
TXG
10 X Genomics Inc
|
7.68 | 1.02B | 631.73M | -239.78M | -33.45M | -2.02 |
![]()
VEEV
Veeva Systems Inc
|
210.08 | 36.39B | 2.75B | 714.14M | 1.09B | 4.33 |
![]()
DOCS
Doximity Inc
|
51.28 | 9.87B | 516.85M | 174.11M | 217.38M | 0.87 |
![]()
TEM
Tempus Ai Inc
|
40.98 | 7.46B | 640.44M | -743.28M | -206.93M | -11.29 |
![]()
HQY
Healthequity Inc
|
80.20 | 7.21B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
WAY
Waystar Holding Corp
|
35.21 | 6.30B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-09-03 | 開始されました | Leerink Partners | Outperform |
2024-07-22 | アップグレード | Jefferies | Hold → Buy |
2024-07-18 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-07-10 | ダウングレード | Deutsche Bank | Buy → Hold |
2024-06-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2024-06-25 | ダウングレード | Guggenheim | Buy → Neutral |
2024-06-03 | 再開されました | Jefferies | Hold |
2024-05-01 | ダウングレード | TD Cowen | Buy → Hold |
2023-12-14 | 開始されました | Guggenheim | Buy |
2023-12-13 | 開始されました | Wolfe Research | Outperform |
2023-12-12 | アップグレード | BofA Securities | Underperform → Neutral |
2023-07-05 | 再開されました | JP Morgan | Overweight |
2023-05-10 | 開始されました | Barclays | Overweight |
2023-03-31 | 開始されました | Stephens | Overweight |
2023-02-02 | 開始されました | UBS | Neutral |
2022-12-14 | 開始されました | Deutsche Bank | Buy |
2022-08-18 | ダウングレード | Goldman | Neutral → Sell |
2022-07-25 | 開始されました | Canaccord Genuity | Buy |
2022-07-15 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-07-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
2021-10-15 | 再開されました | Cowen | Outperform |
2021-09-14 | ダウングレード | BofA Securities | Buy → Neutral |
2021-03-15 | 開始されました | William Blair | Outperform |
2020-12-02 | 開始されました | Goldman | Neutral |
2020-09-09 | 開始されました | Morgan Stanley | Overweight |
2020-07-10 | 開始されました | Stifel | Buy |
2020-03-05 | 開始されました | Guggenheim | Buy |
2020-01-07 | 開始されました | Citigroup | Buy |
2019-10-07 | 開始されました | BofA/Merrill | Buy |
2019-10-07 | 開始されました | Cowen | Outperform |
2019-10-07 | 開始されました | JP Morgan | Overweight |
2019-09-24 | 開始されました | Evercore ISI | Outperform |
すべてを表示
10 X Genomics Inc (TXG) 最新ニュース
Advancing the Future of Biomarker-Driven Immunotherapy - Fierce Biotech
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis (PR Newswire) - Aktiellt
10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
BofA Securities Cuts Price Target on 10x Genomics to $12 From $16, Neutral Rating Maintained - marketscreener.com
10x Genomics (TXG) Price Target Reduced Amid Policy and Economic Concerns | TXG Stock News - GuruFocus
Positive Sentiment Still Eludes 10x Genomics, Inc. (NASDAQ:TXG) Following 29% Share Price Slump - simplywall.st
Spatial Genomics Transcriptomics Market Is Booming Worldwide | - openPR.com
Single-cell Omics Emerging Technologies and Markets Report - GlobeNewswire
Single-cell Omics Emerging Technologies and Markets Report 2025: 10x Genomics, Thermo Fisher & Illumina Lead $9.1 Billion Single-cell Omics Market by 2029 - Yahoo Finance
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know - Yahoo Finance
10x Genomics Reports Third Quarter 2023 Financial Results - Seeking Alpha
10X Genomics stock hits 52-week low at $7.43 amid market challenges - Investing.com Canada
10X Genomics stock hits 52-week low at $7.43 amid market challenges By Investing.com - Investing.com South Africa
IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10X Genomics stock plunges to 52-week low of $9.27 By Investing.com - Investing.com South Africa
10X Genomics stock plunges to 52-week low of $9.27 - Investing.com
We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth - Yahoo Finance
UPC infringement case can resume after EPO upholds 10x Genomics patent - JUVE Patent
10x Genomics Comments on Second UPC Preliminary Injunction Decis - GuruFocus.com
10x Genomics: Lower Cost Innovation May Drive A Rebound - Seeking Alpha
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Long Read Sequencing Market Top Companies Study10X Genomics, - openPR
Bruker motion backfires in US patent dispute with 10x Genomics, Harvard - MLex
Press Release Distribution & PR Platform - ACCESS Newswire
10x Genomics IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire
10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World
Citigroup Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - Defense World
Strategic Move: Healthcare Giant Zimmer Biomet Taps Communications Veteran from 10x Genomics - Stock Titan
10x Genomics gets injunction against Parse Biosciences' ATAC Products - MSN
10x Genomics Dodges Appeal In DNA Analysis Patent Clash - Law 360 UK
10x genomics CEO Serge Saxonov sells $84,393 in stock By Investing.com - Investing.com Australia
Rhumbline Advisers Sells 1,641 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10x genomics CEO Serge Saxonov sells $84,393 in stock - Investing.com
Sanctuary Advisors LLC Purchases 6,474 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
Short Interest in 10x Genomics, Inc. (NASDAQ:TXG) Expands By 34.4% - Defense World
10x Genomics Secures Injunction Against Parse Biosciences' Plann - GuruFocus.com
10x Genomics Secures Injunction Against Parse Biosciences’ Planned ATAC Products - The Malaysian Reserve
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products - Marketscreener.com
10x Genomics secures injunction against Parse Biosciences - Investing.com
10x Genomics gets injunction against Parse Biosciences' ATAC Products (TXG:NASDAQ) - Seeking Alpha
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products – Company Announcement - Financial Times
10 Promising Biotech Stocks to Invest in (March 2025) - Securities.io
ARK Investment Management LLC Purchases 1,193,712 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
SVB Wealth LLC Acquires Shares of 522,609 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Ieq Capital LLC Purchases 50,722 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
ING Groep NV Acquires New Shares in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) CEO Sells $56,368.44 in Stock - MarketBeat
Director of 10x Genomics Picks Up 184% More Stock - Simply Wall St
Oxford Nanopore Expands Compatibility With 10x Genomics To Unlock Deeper Insights in Single-Cell Transcriptomics - Technology Networks
Insider Buying: 10x Genomics, Inc. (NASDAQ:TXG) Director Buys 40,000 Shares of Stock - MarketBeat
10x genomics’ president sells $50,602 in stock - Investing.com India
10 X Genomics Inc (TXG) 財務データ
収益
当期純利益
現金流量
EPS
10 X Genomics Inc (TXG) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Saxonov Serge | Chief Executive Officer |
Feb 28 '25 |
Sale |
10.63 |
7,942 |
84,393 |
871,540 |
大文字化:
|
ボリューム (24 時間):